Protective effect of ligustrazine on accelerated anti-glomerular basement membrane antibody nephritis in rats is based on its antioxidant properties.
Ligustrazine has a renoprotective effect against nephritis. In this study, we further characterized the renoprotective properties of ligustrazine in an experimental model using accelerated anti-glomerular basement membrane antibody (AGBM-Ab). Ligustrazine was given i.p. once daily at 50, 100 mg/kg for 15 days after singly giving i.v. of rabbit anti-rat glomerular basement membrane serum, and showed dose-dependent inhibition the elevation of urinary protein, serum creatinine and blood urea nitrogen as well as the development of glomerular histological changes. Ligustrazine (50 mg/kg) had no affect on glutathione (GSH) content, glutathione peroxidase and catalase activities, but decreased the malondialdehyde (MDA) content and increased superoxide dismutase (SOD) activity in nephritis induced by AGBM-Ab. Ligustrazine (100 mg/kg) significantly decreased MDA content while significantly increased GSH content and SOD, glutathione peroxidase, catalase activities of kidney tissues in the rats treated with AGBM-Ab alone. In conclusion, our results show that ligustrazine has protective activity against accelerated AGBM-Ab nephritis, and its renoprotective effect may be due to its antioxidant properties and inhibition reactive oxygen species (ROS).
Fu
Hong
H
Department of Pharmacology, Basic Medical School, and Center of Laboratory, Zhongnan Hospital, Wuhan University, Wuhan, 430071, P.R. China.
Li
Jing
J
Li
Qi-xiong
QX
Xia
Lin
L
Shao
Lang
L
D000818:Animals; D019867:Anti-Glomerular Basement Membrane Disease / Q000139:chemically induced / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000906:Antibodies; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001323:Autoantibodies; D001806:Blood Urea Nitrogen; D002374:Catalase / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011507:Proteinuria / Q000209:etiology / Q000517:prevention & control; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
D000906:Antibodies; D000975:Antioxidants; D001323:Autoantibodies; D011719:Pyrazines; D017382:Reactive Oxygen Species; C051951:antiglomerular basement membrane antibody; D008315:Malondialdehyde; D003404:Creatinine; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005978:Glutathione; C017953:tetramethylpyrazine